Pharmaceutical compositions comprising meloxicam
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T max of meloxicam of 3 hours or less.
1. A method of treating migraine, comprising orally administering a dosage form once daily to a human being who is experiencing migraine, wherein the dosage form comprises from about 20 mg to about 30 mg of meloxicam or a molar equivalent amount of a salt form of meloxicam, and from about 8 mg to about 13 mg of rizatriptan or a molar equivalent amount of a salt form of rizatriptan, wherein the meloxicam is complexed with a sulfobutylether-β-cyclodextrin, and wherein the dosage form comprises a bicarbonate.
2. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the T max of meloxicam in the human being is less than 60 minutes.
3. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the T max of meloxicam in the human being is about 5×10 1 minutes.
4. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the C max of meloxicam in the human being is from about 2,500 ng/mL to about 3,000 ng/mL.
5. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the C max of meloxicam in the human being is about 3×10 3 ng/mL.
6. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is from about 50,000 ng*hr/mL to about 70,000 ng*hr/mL.
7. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is from about 50,000 ng*hr/mL to about 60,000 ng*hr/mL.
8. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is about 5×10 4 ng*hr/mL.
9. The method of claim 1 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of the bicarbonate; and wherein, upon orally administering the dosage form, the mean elimination half-life is approximately 20 hours for meloxicam.
10. The method of claim 1 , wherein the bicarbonate comprises sodium bicarbonate.
11. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the T max of meloxicam in the human being is less than 60 minutes.
12. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the T max of meloxicam in the human being is about 5×10 1 minutes.
13. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the C max of meloxicam in the human being is from about 2,500 ng/mL to about 3,000 ng/mL.
14. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the C max of meloxicam in the human being is about 3×10 3 ng/mL.
15. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is from about 50,000 ng*hr/mL to about 70,000 ng*hr/mL.
16. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is from about 50,000 ng*hr/mL to about 60,000 ng*hr/mL.
17. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the AUC 0-inf of meloxicam in the human being is about 5×10 4 ng*hr/mL.
18. The method of claim 10 , wherein the dosage form is a solid oral dosage form comprising about 75 mg to about 150 mg of the sulfobutylether-β-cyclodextrin and about 400 mg to about 600 mg of sodium bicarbonate; and wherein, upon orally administering the dosage form, the mean elimination half-life is approximately 20 hours for meloxicam.
19. The method of claim 1 , wherein the human being has acute pain.
20. The method of claim 1 , wherein the dosage form is a tablet.